The patent is licensed exclusively to the company by the patent’s assignee, Supernus Pharmaceuticals.
Based on calculations made by the US Patent and Trademark Office, the term of the patent is 20 years plus 89 days from its filing date of November 4, 2004, or February 1, 2025.